Illumina Partners With Centers Across France to Advance a Precision Medicine Approach for Patients With Late-Stage Cancer – Yahoo Finance

Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease
SAN DIEGO –News Direct– Illumina
SAN DIEGO, February 7, 2022 /3BL Media/ — Illumina, Inc. (NASDAQ:ILMN), today announced an agreement with the Jean Perrin Center at the Clermont-Ferrand University Hospital in France to assess the clinical value of comprehensive genomic profiling (CGP) in cancer therapy options in patients with late-stage disease compared to use of current standard of care, including small panel tests. Evidence from the CELIA (comprehensive genomic profilng impact) research study will be used to support a precision medicine approach for patients with late-stage cancer within the French healthcare system.
The Jean Perrin Center, with participation from the Toulouse Oncopole and the Bordeaux University Hospital Center, will analyze biopsy samples from patients with advanced colorectal, breast, melanoma or lung cancer using CGP enabled by Illumina's TruSight™ Oncology 500 assay.
"We are pleased to be working with the Jean Perrin Center which is leading this important study that will contribute to the growing international evidence base that puts CGP at the forefront of precision oncology medicine," said Phil Febbo, MD, Chief Medical Officer at Illumina. "By assessing many mutations and biomarkers simultaneously to reveal the unique molecular profile of a tumor, CGP is helping to rapidly deliver actionable insights to patients and physicians, and improve outcomes."
TruSight™ Oncology 500 assay can look for the presence of mutations and biomarkers from over 500 genes simultaneously to reveal the specific molecular profile of a cancer sample. This profile can then be matched against precision medicine treatments known to act on specific gene alterations or biomarkers. This approach will be compared by researchers with standard of care testing, including small panel tests that cover a limited range of biomarkers of interest for each cancer type.
"CGP is being increasingly used in cancer centers throughout Europe, including France. Our goal is to confirm the clear clinical utility in order to make next-generation sequencing for metastatic cancer more broadly included in European and national clinical guidelines," said Professor Frédérique Penault-Llorca, General Director of the Jean Perrin Center, and coordinator of the CELIA study. "Data from the CELIA study will add to the growing body of evidence on CGP, with the aim of accelerating the adoption of precision medicine for cancer patients. We are grateful for Illumina's contribution to this project."
"Personalized treatments that target cancer mutations have improved prognosis greatly, helping us direct patients to the best option for them," explained Professor Pascal Pujol, President of the French Society for Predictive and Personalized Medicine, and Head of the Oncogenetics Department at Montpellier University Hospital. "It is critical to ensure that the use of comprehensive analysis based on large DNA and RNA panels becomes part of routine practice so that patients can benefit from the best possible care."
SeqOne Genomics, a French deep tech company offering high performance genomic analysis solutions, has been selected by the three centers for analysis of the data and generation of clinical reports that outline possible treatment options and clinical trial eligibility. Illumina is providing sequencing reagents and biostatistician expertise.
About TruSight Oncology 500 Portfolio
TSO 500 is a Research Use Only pan-cancer assay that enables Comprehensive Genomic Profiling from tissue biopsy samples. Designed to identify known and emerging tumor biomarkers across 523 genes, TSO 500 utilizes both DNA and RNA from tumor samples to identify key variants critical for cancer development and progression, such as small DNA variants, fusions, and splice variants. In addition, the assay assesses key immune-oncology biomarkers, such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI). TSO 500 ctDNA shares similar DNA panel content design to the tissue-based assay but utilizes ctDNA from blood as input material. Due to the TSO 500 portfolio's comprehensive biomarker content, labs can consolidate multiple single gene or small panel workflows into a single assay, saving biopsy specimen and time. Based on the content of TSO 500, Illumina will be adding an in vitro diagnostic (IVD) test to the TSO portfolio. This comprehensive tissue-based tumor profiling assay will have similar chemistry and analytics to TSO 500. To learn more about the TSO 500 portfolio, click here.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:Salli Schwartz858.291.6421IR@illumina.com
Media:Dr. Karen BirminghamEMEA: +44 7500 105665US: 646.355.2111kbirmingham@illumina.com
View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com
View source version on newsdirect.com: https://newsdirect.com/news/illumina-partners-with-centers-across-france-to-advance-a-precision-medicine-approach-for-patients-with-late-stage-cancer-451312431
Rinvoq was recently authorized in the U.S. as a treatment for patients with moderate-to-severe eczema.
Dermata Therapeutics Inc (NASDAQ: DRMA) has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program. The Company said it has already planned and budgeted to conduct both studies. The requests come as DMT310 has been used in clinical trials by over 170 patients exhibiting an acceptable safety and tolerability profile. Further, the FDA approved the Company to use
In New York City in 1920 – nearly two years into a deadly influenza epidemic that would claim at least 50 million lives worldwide – the new year began on a bright note. "Best Health Report for City in 53 Years," boasted a headline in the New York Times on Jan. 4, 1920, after New York had survived three devastating waves of the flu virus. The nation as a whole, which would ultimately lose 675,000 people to the disease, believed that the end might finally be in sight.Subscribe to The Post Most new
This week, the U.S. marked a milestone that seemed unthinkable in the early days of the COVID-19 pandemic: More than 900,000 people have died from the virus. Although the face of the pandemic has changed drastically—there are now effective vaccines, antiviral treatments are on the way, and the latest variant generally produces milder illness despite being much more contagious—experts say it's still important to avoid contracting COVID if at all possible. These are the ways most people get COVID
How a drug used to treat parasites for decades became the hot and controversial drug of the pandemic
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.
Powecom is one of the only KN95 mask brands authorized by the FDA.
Once you get COVID, symptoms are expected to last 5 or 10 days. For some people, however—in fact, an estimated 10 to 30% of people who get COVID—certain symptoms can last for months, years, possibly forever. It's a living nightmare. "Long COVID means the persistence of signs and symptoms that are not explainable by any readily recognizable pathogenic process following the recovery from the acute infection," said Dr. Anthony Fauci, the chief medical advisor to the President and the director of th
By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT Since Our Last Update Since our last update , SQZ Biotechnologies Company (NYSE:SQZ) has made progress on the regulatory front with an investigational new drug (IND) clearance, the addition of strategic advisor John Maraganore, Ph.D. and the publication of preclinical research on SQZ APCs. Highlights since our last update: ➢
New research has linked getting a good night's sleep to cutting calorie intake.
With a high number of COVID-19 cases still on board, coming weeks could see a plateau or decline. But the virus also signals a new normal ahead.
The $55 million fund's first investments include San Francisco cell therapy company Cellevolve, which is working on a treatment for a neurodegenerative disease.
Visceral fat (a.k.a. belly fat) is a particularly dangerous type of body fat with a number of health risks. But excess body fat anywhere is not good news. Subcutaneous fat—the type of body fat that lies under the skin, which you can grab or pinch—can also be excessive and cause problems. What causes subcutaneous body fat? And how do you know if you have too much of it? Read on to find out more—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVI
Vaccine misinformation has played a huge role in the disappointing U.S. turnout, according to a former White House health policy adviser.
In honor of National Black HIV/AIDS Awareness Day, Marvelyn Brown shares her story on becoming HIV positive and what she wants people to know about the virus.
To users, these vapes are identical. But because of an obscure loophole, they skirt the FDA’s regulatory umbrella.
Ten years after receiving a treatment that modifies a patient's own immune cells to attack cancer, two patients who had a form of blood cancer show no signs of the disease, researchers report Wednesday.Why it matters: The patients' remissions hint at how long the effects of CAR-T therapy — a promising but currently very costly treatment— may persist in some people. Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for free“We can now conclude CAR-T cells
World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus said on Saturday that he stressed greater cooperation in investigating the origins of the novel coronavirus during conversations with Chinese officials. In a Twitter thread on Sunday, Tedros said he also spoke with Chinese Premier Li Keqiang about the global goal of vaccinating 70 percent of the world's population this year. "Pleased to meet with Premier Li Keqiang. We discussed #…
Here's a look at the latest COVID-19 numbers for Ohio.
The eyes are often called "the windows to the soul," but more often they can be a window to your health. Experts say that in particular, there's one subtle change that can tip you off to a problem involving your heart. They warn that if you notice this symptom in your eyes, it could signal high cholesterol—and the younger you are, the more likely it is to be the culprit. Read on to find out which ocular symptom could spell trouble for your heart health, and when you shouldn't worry.RELATED: Eati

source

Leave a Comment

Your email address will not be published.

Shopping Cart